Integrative Cancer Therapies最新文献

{"title":"Integrating Traditional Chinese Medicine in Postoperative Rehabilitation for NSCLC: Advancing Evidence-Based Practices.","authors":"Jinyu Wu, Yun Liao","doi":"10.1177/15347354251329897","DOIUrl":"10.1177/15347354251329897","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251329897"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HEalth-Related Quality of Life-Intervention in Survivors of Breast and Other Cancers Experiencing Cancer-Related Fatigue and Associated Cognitive Symptoms Using TraditionAL Chinese Medicine: The 'HERBAL' Trial.","authors":"Alexandre Chan, Daniella Chan, Ding Quan Ng, Huang Fang Zheng, Quan Ming Tan, Chia Jie Tan, Jolene Hui Min Toh, Ning Yi Yap, Yi Long Toh, Yu Ke, Edmund Chun Ann Wang, Queenie Pei Ni Lim, Han Kiat Ho, Lita Chew, Tira J Tan","doi":"10.1177/15347354251314514","DOIUrl":"10.1177/15347354251314514","url":null,"abstract":"<p><strong>Introduction: </strong>As pharmacological strategies remain limited for relieving fatigue and associated cognitive symptoms, integrative modalities such as traditional Chinese medicine (TCM) could be explored as therapeutic strategies in cancer survivors. Here, we evaluate and report the efficacy and safety of a TCM concoction, modified Xiang Bei Yang Rong Tang (XBYRT), on quality of life (QOL), cancer-related fatigue (CRF), and cognitive symptoms, compared to placebo.</p><p><strong>Methods: </strong>In a single-centered, randomized, double-blinded, placebo-controlled pilot trial conducted from 2019 to 2022, fatigued cancer survivors ≥21 years old were recruited to receive the XBYRT intervention or placebo (5% diluted) once daily for the duration of 8 weeks. Patient-reported outcomes for QOL, CRF, cognition, blood samples for biomarker testing, and adverse events were collected at baseline (T0), 4 weeks (T1), 8 weeks (T2), and 10 weeks (T3) after baseline. Linear regression was performed to evaluate differences between groups at T2 and T3.</p><p><strong>Results: </strong>A total of 1502 patients were screened, with 672 patients considered eligible. Of the eligible, 15 XBYRT and 13 placebo subjects with similar mean ages (58.5 vs 58.4) were recruited. Both groups were predominantly Chinese (93% vs 62%), breast cancer patients (87% vs 62%), and diagnosed with stage 2 cancer (60% vs 46%). Although no significant difference was found in QOL between groups, the XBYRT group exhibited improved emotional fatigue at T3 (<i>P</i> = .045) and higher BDNF levels at T2 (<i>P</i> = .047) and T3 (<i>P</i> = .029). After baseline adjustment, XBYRT was associated with better perceived cognitive impairment at T2 (<i>P</i> = .011) and T3 (<i>P</i> = .017), as well as overall perceived cognitive function at T3 (<i>P</i> = .028). XBYRT is well tolerated, with grade 3 adverse events reported in three XBYRT (20%) and two placebo (15%) subjects.</p><p><strong>Conclusion: </strong>In this pilot study, XBYRT as an integrative therapy is safe and generates encouraging improvements in cognitive and fatigue symptoms. Difficulties with recruitment limited the generalizability of trial findings, thus findings should be verified through a larger, multi-centered trial.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251314514"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thanks to Reviewers.","authors":"","doi":"10.1177/15347354251317812","DOIUrl":"https://doi.org/10.1177/15347354251317812","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251317812"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Different Acupuncture Treatments for Cancer-Related Pain: A Systematic Review and Network Meta-Analysis.","authors":"Tianle Xie, Can Liu, Yudi Wu, Xiuxiu Li, Qianyun Yang, Jing Tan","doi":"10.1177/15347354251314500","DOIUrl":"10.1177/15347354251314500","url":null,"abstract":"<p><strong>Background: </strong>Cancer pain is a prevalent and persistent issue, and while there have been some observations of the possible benefits of acupuncture in managing cancer pain, there is still debate regarding its safety and effectiveness. This study aims to compare the efficacy and safety of different acupuncture modalities in the treatment of cancer pain through a network meta-analysis.</p><p><strong>Methods: </strong>Between the time each database was created and June 3, 2024, eight databases were queried: PubMed, Cochrane, Embase, Web of Science, CNKI, Wanfang, VIP, and China Biomedicine. Randomized controlled trials investigating the use of various acupuncture and moxibustion techniques in the treatment of cancer pain were identified. Publication bias and quality of randomized controlled trials were assessed using the Cochrane Risk of Bias tool and the Jadad scale, and network meta-analyses were performed using Stata 15 and R 4.3.2.</p><p><strong>Results: </strong>We incorporated 111 studies encompassing 9549 individuals diagnosed with cancer, examining 29 distinct therapies. Network meta-analysis showed that, compared to Usual Medicine, Acupuncture + Usual Medicine + Traditional Chinese medicine (MD = -1.83, 95% CI: -2.86 to -0.80) could reduce NRS scores, Acupuncture + Traditional Chinese medicine (OR = 30.86, 95% CI: 3.75-254.20) could improve cancer pain relief, Moxibustion + Usual Medicine (MD = 2.12, 95% CI: 0.43-3.80) could effectively improve KPS score, Acupuncture + Application of Chinese medicine (OR = 0.16, 95% CI: 0.04-0.66) is associated with a lower incidence of constipation, Electro-Acupuncture + Usual Medicine (OR = 0.11, 95% CI: 0.03-0.45) shows a lower incidence of nausea and vomiting, Acupuncture + Moxibustion + Usual Medicine (OR = 0.29, 95% CI: 0.09-0.90) is associated with a lower incidence of dizziness.</p><p><strong>Conclusion: </strong>Acupuncture + Traditional Chinese medicine is the best intervention for different acupuncture methods in the treatment of cancer pain, and Moxibustion + Usual Medicine is the best intervention to improve the quality of life of patients.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251314500"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhus Verniciflua Stokes Inhibits PD-1 Expression and Induces Anticancer Effects by Enhancing T Cell Function.","authors":"Seoyoung Kim, Young-Kwan Lee, Wang-Jun Lee, Hyoun Jong Moon, Sanghun Lee","doi":"10.1177/15347354241308220","DOIUrl":"10.1177/15347354241308220","url":null,"abstract":"<p><strong>Background: </strong>Over the last decade, the anticancer effects of <i>Rhus verniciflua</i> Stokes (RVS) have been reported in various preclinical or clinical studies. However, the effects of RVS on immuno-oncology, especially on the functional properties of T cells and their phenotypes, remain unclear. Here, we planned to investigate the impact of RVS on immuno-oncology, specifically focusing on its effects on T cells.</p><p><strong>Methods: </strong>Peripheral blood mononuclear cells (PBMCs) from breast cancer patients were isolated to obtain cytokine-induced killer cell populations with >85% CD3+ T cells. The anticancer activity of these T cells was evaluated by introducing red fluorescent protein (RFP) into HLA-A02:01 type-matched breast cancer cell lines (MCF7 and MDA-MB-231) and analyzing the results using flow cytometry. The effect of RVS extracts on T cell phenotype was assessed using markers such as CTLA-4 and PD-1, as well as mRNA expression levels of key genes (IFN-γ, TNF-α, and IL-2).</p><p><strong>Results: </strong>RVS treatment significantly enhanced the anticancer activity of T cells against breast cancer cells. Specifically, T cells treated with 100 µg/mL of RVS showed a 20.6% increase in cytotoxicity against MCF-7 cells and a 36.2% increase against MDA-MB231 cells compared to the control. Additionally, RVS treatment led to a significant reduction in PD-1 expression on T cells.</p><p><strong>Conclusion: </strong>Our findings demonstrate that RVS treatment enhances T cell function against breast cancer cells by reducing PD-1 expression. These results suggest that components of RVS may serve as potential candidates for restoring exhausted T cells in cancer therapy.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354241308220"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Chinese Medicine on Postoperative Rehabilitation of Non-small Cell Lung Cancer (NSCLC), a Randomized Controlled Study.","authors":"Yifeng Gu, Yichao Wang, Huiling Zhou, Ao Qi, Guanjin Wu, Jiaqi Li, Congmeng Zhang, Yong Yang, Jialin Yao, Wenxiao Yang, Lingzi Su, Yi Liu, Xueqi Tian, Jiajun Song, Yabin Gong, Xiong Qin, Lijing Jiao, Ling Xu","doi":"10.1177/15347354251314529","DOIUrl":"10.1177/15347354251314529","url":null,"abstract":"<p><strong>Background: </strong>With an increasing number of non-small cell lung cancer (NSCLC) patients being offered surgical treatment, postoperative rehabilitation is also being increasingly emphasized. Traditional Chinese medicine (TCM) holds promise for enhancing postoperative recovery, with treatment methods still in refinement. This study aims to evaluate the efficacy of Chinese herbal decoction and Liuzijue exercises in NSCLC patients during the rapid postoperative recovery period.</p><p><strong>Methods: </strong>A randomized, parallel-group clinical trial assigned 50 patients to receive Chinese herbal medicine and Liuzijue exercise plus symptomatic treatment, and 49 to symptomatic treatment alone. Treatment continued until postoperative complications resolved, chest tubes were removed, and no abnormal examination findings were reported. The primary outcome was Quality of Life Questionnare-Core 30 (QLQ-C30) score. Secondary outcomes included MOS item short form 36-Item Short Form Health Survey (SF-36) score, rate of complications, six-minute walk test (6MWT) distance, Leicester Cough Questionnaire (LCQ) score, numerical rating scale (NRS) score, and functional activity score (FAS).</p><p><strong>Results: </strong>Significant improvements in role (MD: 12.15, 95%CI: 2.99-21.32, <i>P</i> < .05) and social functioning (MD: 10.25, 95%CI: 1.72-18.78, <i>P</i> < .05) were observed in the intervention group vs. controls, as measured by QLQ-C30. The intervention group showed better post-treatment SF-36 scores in Role-Physical (RP), Social Function (SF), Role-Emotional (RE), and Mental Health Summary (MCS) (<i>P</i> < .05). The complication rate was lower in the intervention (20.00%) than the control group (44.44%) (<i>P</i> < .05). The intervention group also had a significant increase in FAS scores (<i>P</i> < .05) and covered a better 6MWT distance (<i>P</i> < .05).</p><p><strong>Conclusion: </strong>Chinese herbal decoction and Liuzijue exercises during the rapid recovery period after lung cancer surgery enhanced patients' QoL and physical endurance, and mitigated complications.<b>Trial registration:</b> This tial was registered with chictr.org.cn (Registration number:ChiCTR2100044776).</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251314529"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11803757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study.","authors":"Hsuan-Ting Tang, Shi-Chen Ou, Chien-Lun Chu, Ai-Lin Lee, Hung-Jen Lin, Ying-Chun Lin, Yao-Ching Wang, Shih-Neng Yang, Ming-Yu Lien","doi":"10.1177/15347354251326946","DOIUrl":"10.1177/15347354251326946","url":null,"abstract":"<p><p>The objective of this study was to evaluate the efficacy of the traditional Chinese herbal medicine formula, San-Zhong-Kui-Jian-Tang (SZKJT), on patients with head and neck cancer who underwent concurrent chemoradiotherapy (CCRT). We performed a single-center, open-label, prospective feasibility study from 2018 to 2020. A total of 27 head and neck cancer patients who received CCRT were recruited for the study. SZKJT was given to patients simultaneously with CCRT for 9 weeks. The primary endpoint was the feasibility and completion rate of CCRT, while the secondary endpoint was occurrence of adverse effects. The quality of life (QoL) and traditional Chinese medicine body constitutions were measured by the QLQ-C30 and the Body Constitution Questionnaire (BCQ), respectively. There were 6 dropouts from the study due to complications, while 21 participants completed the trial. Among those 21 participants, 16 completed the CCRT treatment course, yielding a completion rate of 76.2%. The side effects observed during the CCRT and SZKJT trial included dermatitis in 4.8% (Grade 0), 57.1% (Grade 1), and 38.1% (Grade 2), and oral mucositis in 62.0% (Grade 1), 19.0% (Grade 2), and 19.0% (Grade 3) of participants. A comparison of the pre- and post-treatment QLQ-C30 scores revealed that QoL was unaffected (<i>P</i> = .506). However, the BCQ results showed significant increases in the Yin-Xu, Yang-Xu, and stasis constitutions (<i>P</i> < .001). No serious adverse events were observed due to SZKJT. Preliminary results indicated that additional SZKJT with CCRT was feasible, while noting a high completion CCRT rate (76.2%) among the SZKJT-treated patients. Our study reveals that SZKJT can effectively reduce the severity of dermatitis and oral mucositis associated with CCRT. Larger randomized controlled trials are required to further assess the efficacy and safety of SZKJT.The trial registration number is NCT05590650 on ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05590650.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251326946"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the E-Psycho-Oncological Short-Term Intervention \"By Your Side\" to Reduce Cancer-Related Distress: A Pilot Study.","authors":"Sven Erik Strunk, Johanna Graf, Julia Barbara Krakowczyk, Alexandra Wieser, Jana Heinen, Caterina Schug PhD, Lisa Maria Jahre, Eva-Maria Skoda, Yesim Erim, Martin Teufel, Alexander Bäuerle","doi":"10.1177/15347354251320047","DOIUrl":"10.1177/15347354251320047","url":null,"abstract":"<p><strong>Objective: </strong>A large number of patients with cancer experience distress, but not all of them receive adequate psychological support. The e-psycho-oncological short-term intervention \"By your Side\" was developed to offer evidence-based and low-threshold support for cancer patients dealing with distress.</p><p><strong>Methods: </strong>A longitudinal intervention pilot study was conducted from 4 March 2022 to 4 January 2023. N = 91 participants took part in the study. N = 82 completed the first module, while n = 23 successfully completed the whole intervention and were included in the final data analyses. \"By your Side\" consists of 16 modules based on cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction. Differences in distress between the baseline (T0), post-intervention (T1), and follow-up (T2) were analyzed using an ANCOVA and post-hoc <i>t</i>-tests. Secondary outcomes (anxiety, depression, mindfulness, and self-efficacy) were also compared between measuring points, using ANOVAs and post-hoc tests.</p><p><strong>Results: </strong>A significant reduction (<i>p</i>_adj = 0.014, <i>d</i> = 0.654) in distress from baseline (T0, <i>M</i> = 52.68, SD = 16.34) to follow-up (T2, <i>M</i> = 43.84, SD = 17.59) was observed. There was a significant decrease in anxiety symptoms and a significant increase in mindfulness and self-efficacy. The user's satisfaction (<i>M</i> = 28.00, range 8-32) and the usability (<i>M</i> = 89.57, range 0-100) of the intervention were high.</p><p><strong>Conclusion: </strong>The study provides preliminary evidence that the e-psycho-oncological short-term intervention \"By your Side\" can successfully reduce the distress of cancer patients. The high dropout rate (74.7%) must be taken into account.</p><p><strong>Trial registration: </strong>German Clinical Trial Register (https://www.drks.de/search/de/trial/DRKS00036001), DRKS number: 00036001 (retrospectively registered).</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251320047"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction of Senescence in Lung Cancer Cells by Qidongning Formula via the Transcription Factor EGR1.","authors":"Di Zhou, Wen-Xiao Yang, Cheng-Yan Wang, Cheng-Xin Qian, Ling Xu, Chang-Sheng Dong, Jie Chen, Ya-Bin Gong","doi":"10.1177/15347354241307007","DOIUrl":"10.1177/15347354241307007","url":null,"abstract":"<p><p><b>Background:</b> The purpose of this study was to investigate the role of the early growth response gene 1 (EGR1) in inducing senescence in lung cancer cells by Qidongning Formula (QDF). <b>Methods:</b> Cell-Counting-Kit-8 was used to study the effect of QDF on A549 and NCI-H1975 cells proliferation. Senescence-associated β-galactosidase (SA-β-GAL) staining was used to examine the effect of QDF on cellular senescence. RT-qPCR analyses and Western blot were used to monitor the expression of EGR1 and the senescence-associated proteins p21 and p53. A rescue assay using an EGR1-overexpressing vector to explore whether EGR1 is a key target gene of QDF-induced lung cancer senescence. Bioinformatics analyses were used to identify the regulatory network involved in the process of QDF-induced senescence in lung cancer cells, downstream of EGR1 activation. <b>Results:</b> QDF could inhibit the proliferation of lung cancer cells in a concentration- and time-dependent manner. SA-β-GAL assay showed that QDF can induce lung cancer cells senescence, an increase in QDF concentration led to a significant increase in the number of cells that stained positive in the SA-β-GAL assay in the group exposed to a higher concentration of QDF. Western blot and RT-qPCR analyses indicated that the expression levels of the p53 and p21 proteins in A549 and H1975 cells increased significantly after QDF intervention. Additionally, EGR1-overexpressing can enhance QDF-induced senescence in lung cancer cells. Bioinformatics analyses revealed the EGR1 target genes implicated in QDF-induced senescence in A549 cells, including 21 senescence-related genes. <b>Conclusion:</b> The present study suggests QDF induces cellular senescence through activation of EGR1 in lung cancer cells and provides an insight for understanding the antitumor mechanisms of this Chinese traditional medicine.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354241307007"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Ayurveda in Prostate Cancer Management.","authors":"Parnian Jabbari, Omid Yazdanpanah, David J Benjamin, Arash Rezazadeh Kalebasty","doi":"10.1177/15347354251330906","DOIUrl":"https://doi.org/10.1177/15347354251330906","url":null,"abstract":"<p><p>Ayurveda is commonly utilized in the treatment of medical ailments but has yet to gain traction in incorporation into allopathic medicine. Prostate cancer is the most common cancer among men and presents a significant public health burden across the globe. Despite advancements in the management of advanced prostate cancer including androgen deprivation therapy and novel hormonal therapies, men may eventually develop resistance to hormonal therapy. As such, there is an urgent need for novel therapeutic options in treating this malignancy. This review examines the pre-clinical evidence for Ayurveda medicinal plants such as <i>Withania somnifera</i>, <i>Glycyrrhiza</i> spp, <i>Momordica</i> spp, <i>Boswellia</i>, and <i>Bacopa monnieri</i> and their potential application in managing prostate cancer. Several in-vitro and pre-clinical studies suggest potentials for these plants or their derivatives in preventing or treating prostate cancers. Despite strong evidence of efficacy of these plants to potentially improve the outcome of prostate cancer, clinical trials are required to evaluate which plants may be most efficacious and to determine effective dosing strategies, as well as the use of ayurvedic plants as standalone therapies or in combination with conventional prostate cancer treatments.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251330906"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}